Dasatinib
PD-1
The Affiliated Hospital of Qingdao UniversitySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
7 Active assets in the PD-1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Shandong New Time Pharmaceutical Co., LTD | Phase 2 | CCC |
Ruxoprubart Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 | CCC |
LENVATINIB The First Affiliated Hospital with Nanjing Medical University | Phase 2 | CCC |
f520 Shandong New Time Pharmaceutical Co., LTD | Phase 2 | CCC |
Tuvonralimab Anhui Provincial Hospital | Phase 2 | CCC |
pd-1 knockout engineered t cells Ruijin Hospital | Phase 1 | CC |
pd1-til Ruijin Hospital | Phase 1 | CC |
Same molecule, other indications
Dasatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →